Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: Classification of variables associated with disease outcome-Reference-Cited by-同舟云学术

Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: Classification of variables associated with disease outcome

Published:1985 Issue:1 Volume:7 Page:31-39
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Koutsilieris Michael,Tolis George

Publisher

Wiley

Subject

Urology,Oncology

Reference14 articles.

1. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

2. SUSTAINED SUPPRESSION OF TESTOSTERONE PRODUCTION BY THE LUTEINISING-HORMONE RELEASING-HORMONE AGONIST BUSERELIN IN PATIENTS WITH ADVANCED PROSTATE CARCINOMA

3. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma

4. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma

5. Suppression of testicular steroidogenesis by the GnRH agonistic analogue buserelin (HOE-766) in patients with prostatic cancer: Studies in relation to dose and route of administration

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of medical castration on lipid levels in black South African men with prostate cancer;African Journal of Urology;2022-12

2. Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers;International Journal of Molecular Sciences;2022-01-22

3. Differential Expression of IGF-I Transcripts in Bladder Cancer;Anticancer Research;2018-05-30

4. Risk of new-onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population;Journal of Diabetes;2014-12-22

5. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists for Chinese men with prostate cancer;Asian Journal of Andrology;2014